Project 1 Abstract The goals of Project 1 are to design and evaluate new versions of SOSIP trimers based on a range of HIV-1 genes with mutations to improve their structural, antigenic and immunogenic properties. The trimers designed in Project 1, with structure-based input from Project 2, are produced by Core B, provided to Project 2 for structural studies, assessed for antigenicity by Project 1, and sent to multiple collaborators for additional research, including animal immunogenicity studies. Project 1 will be closely involved in the overall scientific program. Dr. John P. Moore, will direct Project 1, at the Weill Cornell Medical College, New York. Dr. Rogier W. Sanders will lead a component at the Amsterdam University Medical Centers, Amsterdam.
The Specific Aims are:
Aim 1 : To design Env trimers that can induce bNAb responses. We will design new and redesign existing SOSIP trimers by using high-resolution structures and animal immunogenicity data. We will create SOSIP trimer variants that target germline bNAb precursors (gl-bNAbs). We will further improve the overall SOSIP trimer ?recipe? for use with any given Env sequence, as trimers from multiple clades are likely to be necessary to steer NAb responses towards breadth. We will focus responses to bNAb epitopes on SOSIP trimers, by eliminating unwanted holes in glycan shields and by masking non-NAb epitopes that may act as decoys, including neo-epitopes on the trimer base. The overall goals are to better present mature-bNAb and gl-bNAb epitopes to the immune system, and drive Ab evolution toward bNAb development.
Aim 2 : To enhance the potency and durability of antibody responses by presenting SOSIP trimers particulate immunogens and incorporating T-helper epitopes. We will chemically couple SOSIP trimers to Iron Oxide nanoparticles (NP, 25-50 nm) to use as immunogens for priming antibody responses. To compensate for well-known deficiencies in endogenous Env-encoded T-cell helper epitopes, we will incorporate exogenous T-cell helper epitopes into the soluble and NP-presented SOSIP trimers. The overall goals are to overcome limitations to the immunogenicity of HIV-1 Env proteins in general.
Aim 3 : To design and evaluate animal immunogenicity studies using SOSIP trimers. Our team has well-established collaborations with several groups as well as access to other non-NIH funding support that together enable it to conduct animal immunization studies that are not directly paid for by this award. Project 1 will work with collaborators to design immunogenicity experiments and contribute to the analysis and interpretation of these studies by performing neutralization, NAb-epitope mapping and related serology assays. The overall goals are to further advance the design of SOSIP trimers and trimer-based vaccination regimens that are capable of inducing bNAbs.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
3P01AI110657-06S1
Application #
10336286
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Chakrabarti, Bimal Kumar
Project Start
2015-06-01
Project End
2021-05-31
Budget Start
2020-06-01
Budget End
2021-05-31
Support Year
6
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Type
DUNS #
060217502
City
New York
State
NY
Country
United States
Zip Code
10065
Ozorowski, Gabriel; Cupo, Albert; Golabek, Michael et al. (2018) Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers In Vitro. J Virol 92:
Struwe, Weston B; Chertova, Elena; Allen, Joel D et al. (2018) Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen. Cell Rep 24:1958-1966.e5
Behrens, Anna-Janina; Kumar, Abhinav; Medina-Ramirez, Max et al. (2018) Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages. J Proteome Res 17:987-999
Ringe, Rajesh P; Pugach, Pavel; Cottrell, Christopher A et al. (2018) Closing and opening holes in the glycan shield of HIV-1 envelope glycoprotein SOSIP trimers can redirect the neutralizing antibody response to the newly unmasked epitopes. J Virol :
Allen, Joel D; Sanders, Rogier W; Doores, Katie J et al. (2018) Harnessing post-translational modifications for next-generation HIV immunogens. Biochem Soc Trans 46:691-698
Klasse, P J; Ketas, Thomas J; Cottrell, Christopher A et al. (2018) Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques. PLoS Pathog 14:e1006913
de Taeye, Steven W; de la Peña, Alba Torrents; Vecchione, Andrea et al. (2018) Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers. J Biol Chem 293:1688-1701
Dey, Antu K; Cupo, Albert; Ozorowski, Gabriel et al. (2018) cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate. Biotechnol Bioeng 115:885-899
Torrents de la Peña, Alba; Sanders, Rogier W (2018) Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies. Retrovirology 15:63
Medina-Ramírez, Max; Sanders, Rogier W; Sattentau, Quentin J (2017) Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. Curr Opin HIV AIDS :

Showing the most recent 10 out of 51 publications